Vertex to acquire Crinetics in $10 billion deal to expand endocrinology portfolio
read at Endpoints ↗DealPositive
Vertex Pharmaceuticals announced it will acquire Crinetics Pharmaceuticals for $10 billion, the largest purchase in the company's history.
The transaction is aimed at broadening Vertex's commercial portfolio, especially in the endocrinology area where Crinetics operates.
The deal was disclosed on Monday afternoon and will close subject to standard regulatory approvals.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Vertex makes $10B deal for commercial endocrinology biotech Crinetics”
read at Endpoints ↗83 words · retrieved Jul 6
comments(0)
5-min edit window · permanent after that